Patients with plaque psoriasis treated with Johnson & Johnson’s oral IL-23 inhibitor JNJ-2113 have been shown to maintain skin clearance for up to a year, pointing to
In this instalment of our week-by-week clinical trials round-up, we look at life sciences research and development announced during the week of 12th to 16th February, from early-stage onwar
European life sciences investor Medicxi has bundled together six privately-held companies with dermatology medicines in development under a single drugmaker – called Alys
Almirall has taken another step forwards in the development of a digital approach to managing and treating dermatological conditions, forming a three-year alliance with Mi
Dermatology specialist LEO Pharma has built the case for its first-in-class chronic hand eczema (CHE) drug delgocitinib, saying it outperformed the only approved drug ther
India’s Sun Pharma has signed an agreement to take full control of Israeli generic drugmaker Taro Pharmaceutical Industries, taking it into private hands.
South Korea’s Hyundai Bioscience is preparing to start clinical trials of what it hopes could become the first antiviral treatment for dengue fever, a mosquito-borne viral
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.